Nodify Lung Test: Blood Biomarker for Lung Nodules

The Nodify suite of tests (Nodify CDT and Nodify XL2) is a blood biomarker panel marketed for risk stratification of indeterminate pulmonary nodules. The goal: distinguish high-risk from low-risk nodules to guide workup. This light guide explains how Nodify works, when it's useful, and what alternatives exist.

What Nodify Tests Measure

The Nodify panels (developed by Biodesix) measure two distinct biomarker categories:

• Nodify CDT: autoantibodies against tumor-associated antigens
• Nodify XL2: serum protein biomarkers (LG3BP and C163A) using a proteomic classifier

Both tests aim to identify nodules with higher probability of being malignant.

When Nodify Is Used

The intended clinical context:

• Indeterminate pulmonary nodule (typically 8-30 mm)
• Patient is a candidate for biopsy or surveillance
• Risk model + imaging features alone don't clearly indicate next step

A "high-risk" Nodify result might push toward biopsy; a "low-risk" result might support continued surveillance.

Sensitivity and Limitations

The Nodify XL2 manufacturer reports:

• Sensitivity ~98% for low-likelihood reclassification
• Specificity ~33% for low-likelihood reclassification
• Negative predictive value useful for nodules with pre-test probability 5-50%

Limitations:

• Best for nodules in the indeterminate probability range
• Not useful for clearly benign or clearly malignant nodules
• Cost is substantial ($3,000-5,000 US cash)
• Insurance coverage variable
• Not widely adopted outside the US

Alternative Approaches

For risk stratification of indeterminate nodules:

PET-CT ($3,500-6,500 US):
- Direct visualization of metabolism
- SUVmax >2.5 raises suspicion
- Limited by partial volume in nodules <8 mm

Tissue biopsy ($4,000-9,000 US):
- Definitive answer
- Invasive; 15-25% pneumothorax rate for CT-guided
- 90%+ diagnostic yield for peripheral lesions

Continued LDCT surveillance:
- Lower cost
- Volume doubling time over 3 months can stratify risk
- 100-400 day doubling time suggests cancer

Lung-RADS classification:
- Standard radiology-based stratification
- No additional test needed
- Embedded in routine LDCT reports

For interpretation of lung nodule findings, our team can help.

Availability

Nodify tests are commercially available primarily in the US. Outside the US:

• UK: not standardly available
• Mainland China: not commonly used; PET-CT is preferred
• Other countries: limited availability

For international patients, the standard pathway is imaging (LDCT, PET-CT) and biopsy if indicated, without Nodify.

When the Test Adds Value

Nodify may add value when:

• The clinical question is "biopsy or surveillance?"
• Pre-test malignancy probability is in the 10-50% range
• Insurance covers the test
• The physician is comfortable using biomarker results in management

It adds less value when:

• Clinical decision is already clear
• Pre-test probability is very low (<10%) or very high (>50%)
• Insurance doesn't cover (cost prohibitive)
• Treatment plan doesn't depend on the result

Frequently Asked Questions

Can Nodify replace biopsy?
No. For nodules requiring tissue diagnosis, biopsy is the definitive test. Nodify is a triage tool, not a diagnostic test.

Is Nodify FDA approved?
The Nodify XL2 test is FDA cleared for the specific indication of risk reclassification in indeterminate pulmonary nodules.

Will my insurance cover Nodify?
Some commercial insurers cover for specific indications. Medicare coverage is variable. Out-of-pocket cost $3,000-5,000 in the US.

Are there international alternatives?
For risk stratification in indeterminate nodules: PET-CT is the standard approach worldwide. Continued LDCT with growth assessment is also routine. Biopsy when indicated.

Need Help Booking?

SinoCareLink can pre-book PET-CT or biopsy at a top Chinese hospital for indeterminate lung nodule workup, translate reports into English, and arrange airport pickup. Contact us for a free consultation.